The Open Group OSDU™ Forum Launches the OSDU Data Platform Mercury Release
24.3.2021 12:00:00 EET | Business Wire | Press release
The Open Group, the vendor-neutral technology consortium, today announced the OSDU Data Platform Mercury Release. Developed by The Open Group OSDU™ Forum, the OSDU Data Platform is an Open Source, standards-based and technology-agnostic data platform for the energy industry that stimulates innovation, industrializes data management, and reduces time to market for new solutions.
The OSDU Data Platform will provide over time access to a vast portfolio of open and proven vendor-developed applications from a broad range of energy sources. By accessing this ecosystem, developers no longer have to develop and maintain the monolithic architecture needed to deliver unique value-add services. Now, with a single set of well-defined and industry-specific APIs, organizations can easily accelerate platform design and develop proprietary applications on top of the OSDU Data Platform.
With an Open Source approach, any company – from established corporations to start-up challenger companies – can contribute new features to the platform, supporting a variety of business workflows. All work is validated by the OSDU Program Management Committee (PMC) to ensure it is aligned with the overall direction of the Forum.
With a single view of industry data, the OSDU Data Platform can be harnessed for innovative business applications. The Mercury Release of the OSDU Data Platform is now available to Operators and Software Developers who want to:
- Liberate data from traditional silos and make all data discoverable and usable in a single data platform
- Enable new integrated exploration and development workflows that reduce overall cycle time
- Take advantage of emerging digital solutions to provide scalability and accelerate decision making
Steve Nunn, President and CEO of The Open Group, commented: “The OSDU Data Platform Mercury Release represents an important achievement by the OSDU Forum in a very short space of time. Established in 2018, the OSDU Forum has accumulated over 185 Member organizations who are collaborating together to accelerate innovation and reduce costs in the energy sector. With a standard data platform, energy companies will be able to drive innovation by integrating digital technologies and utilizing open standards for better decision making. Looking ahead, this will be imperative to meet the world’s increasing energy demands while reducing greenhouse gas emissions.”
Johan Krebbers, GM Emerging Digital Technologies / VP IT Innovation, Shell, commented: “At the heart of most energy companies’ strategies is embracing the transformational technologies taking us forward in today’s digital era. This makes the need for a common architectural design clear, one that underpins how our industry works with its data.”
David Eyton, EVP Innovation & Engineering, bp, commented: “Data is at the heart of bp’s transformation into an integrated energy company. We believe that the future of the energy industry will be data driven and dependent on its ability to manage data in a manner that promotes data sharing with partners, innovation through data science, and rapid decision making throughout the lifecycle of the energy value chains. Being a founding member of the OSDU Forum, bp has had an opportunity to be part of an organization that is fundamentally changing the data landscape for our industry. By integrating energy organizations, cloud services providers, and software vendors, the OSDU Forum is providing an opportunity for collaboration that will be beneficial for all involved. We are very excited about the Mercury Release of the OSDU Data Platform and look forward to expanding this approach into engineering, emissions, and new energy.”
To learn more about how to develop applications the OSDU Data Platform, visit the application developer community page here.
The current OSDU Forum Member List is available here.
-ENDS-
About The Open Group OSDU Forum
The Open Group OSDUTM Forum enables the Energy industry to develop transformational technology to support the world’s changing Energy needs. The OSDU Forum is available to all energy stakeholders including application developers, service operators, technology providers, software companies, academia, and more. More information on the OSDU Forum can be found here.
About The Open Group
The Open Group is a global consortium that enables the achievement of business objectives through technology standards. Our diverse membership of more than 800 organizations includes customers, systems and solutions suppliers, tool vendors, integrators, academics, and consultants across multiple industries. For more information, visit www.opengroup.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005005/en/
Contact information
Media Contact:
Jenny Morris
Hotwire
+44 (0)7393465529
UKOpengroup@hotwirepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
